Switching from inhaled to pill for PAH
Treatments studied
Part of Lungs & breathing clinical trials.
This study looks at how patients feel and how well they stick with their treatment when they switch from an inhaled medicine (iloprost) to a pill (selexipag) for pulmonary arterial hypertension (PAH). It will help doctors understand if the switch improves patient experience.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of pulmonary arterial hypertension (PAH) from a heart catheterization test.
- You are currently using the inhaled medicine iloprost for your PAH.
- Your doctor has decided it's time to switch from iloprost to the pill selexipag.
- You are able to fill out questionnaires about how you feel.
- You are willing to provide written permission to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether changing from the oral medicine selexipag to an inhaled treatment called treprostinil (LIQ861) can improve symptoms or be better tolerated in adults with pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs. If you are currently taking selexipag but it isn't working well enough or causes side effects, this switch might be a good option for you.
This trial studies the long-term effects of the drug selexipag in people whose pulmonary arterial hypertension is caused by schistosomiasis, a parasitic infection. It aims to see if adding selexipag improves outcomes for those already on standard treatments.
This study compares two approaches for people with PAH whose current treatment (a combination of sildenafil and an endothelin receptor antagonist) needs to be stepped up. Half the participants will add a third medicine (iloprost or selexipag), while the other half will increase their sildenafil dose. The goal is to see which strategy works better for improving symptoms and lowering risk.
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
This trial compares starting with two oral medications versus one for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have conditions like high blood pressure, diabetes, obesity, or heart disease. The goal is to see if a two-drug approach works better for patients with these additional health issues.
This study looks at how changing from one PAH medicine (ambrisentan) to another (bosentan) affects your disease risk over time. It compares people who made the switch to those who stayed on ambrisentan.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.